$CWBR
CohBar Inc

2023 Q2 Form 10-Q Financial Statement

#000121390023039321 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.254M $1.279M $1.745M
YoY Change 878.14% -26.69% 28.3%
% of Gross Profit
Research & Development $178.9K $1.021M $1.506M
YoY Change -84.93% -32.24% -43.16%
% of Gross Profit
Depreciation & Amortization $920.00 $63.48K $32.80K
YoY Change -97.15% 93.54% -18.0%
% of Gross Profit
Operating Expenses $4.433M $2.300M $3.251M
YoY Change 61.58% -29.26% -18.92%
Operating Profit -$4.433M -$2.300M -$3.251M
YoY Change 61.58% -29.26%
Interest Expense $101.0K $134.2K -$10.55K
YoY Change 439.53% -1371.66% -47.25%
% of Operating Profit
Other Income/Expense, Net $101.0K $134.2K -$10.55K
YoY Change 439.6% -1372.03%
Pretax Income -$4.332M -$2.166M -$3.262M
YoY Change 58.99% -33.6% -19.26%
Income Tax
% Of Pretax Income
Net Earnings -$4.332M -$2.166M -$3.262M
YoY Change 58.99% -33.6% -19.23%
Net Earnings / Revenue
Basic Earnings Per Share -$1.49 -$0.75 -$1.13
Diluted Earnings Per Share -$1.49 -$0.75 -$37.61K
COMMON SHARES
Basic Shares Outstanding 2.907M shares 2.907M shares 2.891M shares
Diluted Shares Outstanding 2.907M shares 2.907M shares 2.891M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.31M $14.08M $23.53M
YoY Change -38.74% -40.15% 32.03%
Cash & Equivalents $6.192M $5.392M $1.564M
Short-Term Investments $6.119M $8.689M $21.96M
Other Short-Term Assets $119.7K $237.3K $375.4K
YoY Change -88.79% -36.78% 10.41%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.47M $14.32M $23.90M
YoY Change -41.07% -40.1% 31.63%
LONG-TERM ASSETS
Property, Plant & Equipment $1.728K $2.335K $228.1K
YoY Change -99.12% -98.98% -36.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $13.48K $63.57K $76.60K
YoY Change -82.41% -17.01% 9.43%
Total Long-Term Assets $32.67K $83.68K $323.7K
YoY Change -88.79% -74.15% -28.06%
TOTAL ASSETS
Total Short-Term Assets $12.47M $14.32M $23.90M
Total Long-Term Assets $32.67K $83.68K $323.7K
Total Assets $12.51M $14.40M $24.23M
YoY Change -41.72% -40.55% 30.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.376M $532.4K $640.7K
YoY Change 345.79% -16.9% -38.98%
Accrued Expenses $498.4K $49.51K $583.1K
YoY Change 550.06% -91.51% -48.4%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $3.002M $898.5K $1.224M
YoY Change 303.57% -26.58% -50.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.002M $898.5K $1.224M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $3.002M $898.5K $1.224M
YoY Change 303.57% -26.58% -56.45%
SHAREHOLDERS EQUITY
Retained Earnings -$103.4M -$99.08M
YoY Change 13.98%
Common Stock $2.907K $2.907K
YoY Change -96.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.504M $13.50M $23.00M
YoY Change
Total Liabilities & Shareholders Equity $12.51M $14.40M $24.23M
YoY Change -41.72% -40.55% 30.18%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$4.332M -$2.166M -$3.262M
YoY Change 58.99% -33.6% -19.23%
Depreciation, Depletion And Amortization $920.00 $63.48K $32.80K
YoY Change -97.15% 93.54% -18.0%
Cash From Operating Activities -$1.803M -$1.628M -$2.519M
YoY Change -47.15% -35.35% -39.16%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $2.603M $1.090M -$735.0K
YoY Change -44.92% -248.3% -134.67%
Cash From Investing Activities $2.603M $1.090M -$735.0K
YoY Change -44.92% -248.3% -134.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -174.4K
YoY Change -118.55%
NET CHANGE
Cash From Operating Activities -1.803M -$1.628M -2.519M
Cash From Investing Activities 2.603M $1.090M -735.0K
Cash From Financing Activities 0.000 -174.4K
Net Change In Cash 800.0K -$538.3K -3.428M
YoY Change -39.13% -84.3% 217.42%
FREE CASH FLOW
Cash From Operating Activities -$1.803M -$1.628M -$2.519M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 cwbr Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue
usd
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-38326
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1299952
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1455 Adams Drive
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1308
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Menlo Park
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94025
CY2023Q1 dei City Area Code
CityAreaCode
(650)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
446-7888
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
CWBR
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2906926 shares
CY2023Q1 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5392390 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5930731 usd
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
8688947 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
9806591 usd
CY2022Q4 cwbr Vendor Receivable
VendorReceivable
27500 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
237300 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
453681 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
14318637 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
16218503 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2335 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65509 usd
CY2023Q1 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
17776 usd
CY2022Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
18083 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
63572 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
63572 usd
CY2023Q1 us-gaap Assets
Assets
14402320 usd
CY2022Q4 us-gaap Assets
Assets
16365667 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
532423 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
180104 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
49513 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
327868 usd
CY2023Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
316605 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
525666 usd
CY2023Q1 us-gaap Liabilities
Liabilities
898541 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1033638 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
12000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
12000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2906926 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2906926 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2906926 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2906926 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
2907 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2907 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
112575993 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
112238392 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99075121 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-96909270 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
13503779 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15332029 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14402320 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16365667 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1020739 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1506308 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1279273 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1744918 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
2300012 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
3251226 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2300012 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3251226 usd
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
134161 usd
CY2022Q1 us-gaap Interest Expense Other
InterestExpenseOther
1824 usd
CY2022Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-8723 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
134161 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10547 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2165851 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3261773 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.13
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2906926 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2890878 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15332029 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
337601 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2165851 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
13503779 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25607827 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
456423 usd
CY2022Q1 cwbr Sale Of Common Stock In Atm Net
SaleOfCommonStockInATMNet
200624 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3261773 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
23003101 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2165851 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3261773 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
63481 usd
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
32801 usd
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
22975 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
337601 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
456423 usd
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
8350 usd
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
373 usd
CY2023Q1 cwbr Discount On Investments
DiscountOnInvestments
50644 usd
CY2022Q1 cwbr Discount On Investments
DiscountOnInvestments
18048 usd
CY2023Q1 cwbr Vendor Receviables
VendorReceviables
-27500 usd
CY2022Q1 cwbr Vendor Receviables
VendorReceviables
-173499 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-216381 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-151999 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
352319 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
268700 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-278355 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-59235 usd
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-209061 usd
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-307994 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1628316 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2518809 usd
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
22975 usd
CY2022Q1 cwbr Payment For Security Deposit
PaymentForSecurityDeposit
6976 usd
CY2023Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
8773000 usd
CY2022Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
21983000 usd
CY2023Q1 cwbr Proceeds From Redemptions Of Investments
ProceedsFromRedemptionsOfInvestments
9840000 usd
CY2022Q1 cwbr Proceeds From Redemptions Of Investments
ProceedsFromRedemptionsOfInvestments
21255000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1089975 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-734976 usd
CY2022Q1 cwbr Proceeds From The Atthe Market Offering Net
ProceedsFromTheAttheMarketOfferingNet
200624 usd
CY2022Q1 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-375000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-174376 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-538341 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3428161 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5930731 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4992145 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5392390 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1563984 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
114411 usd
CY2023Q1 us-gaap Investments And Cash
InvestmentsAndCash
14100000 usd
CY2023Q1 cwbr Working Capital
WorkingCapital
13400000 usd
CY2023Q1 us-gaap Stockholders Equity Other
StockholdersEquityOther
13500000 usd
CY2023Q1 cwbr Net Loss Amount
NetLossAmount
2200000 usd
CY2023Q1 us-gaap Percentage Of Interest Bearing Domestic Deposits To Deposits Money Market
PercentageOfInterestBearingDomesticDepositsToDepositsMoneyMarket
0.85 pure
CY2023Q1 us-gaap Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
10500 shares
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2023Q1 cwbr Share Based Compensation Arrangement By Share Based Payment Award Option Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross
usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. Actual results could differ from these estimates. The Company’s significant estimates and assumptions include the fair value of financial instruments, stock-based compensation and the valuation allowance relating to the Company’s deferred tax assets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b><i> </i></b></span></p>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b><i>Concentrations of Credit Risk</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The Company maintains deposits in a financial institution which is insured by the Federal Deposit Insurance Corporation (“FDIC”). At various times, the Company has deposits in this financial institution in excess of the amount insured by the FDIC. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b><i> </i></b></span></p>
CY2023Q1 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
8700000 usd
CY2022Q4 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
9800000 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
3900000 usd
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
3900000 usd
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2906926 shares
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
usd
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3000000 usd
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1430309 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1560408 shares
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
usd
CY2022Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
usd
CY2023Q1 cwbr Payment For Security Deposit
PaymentForSecurityDeposit
usd
CY2023Q1 cwbr Proceeds From The Atthe Market Offering Net
ProceedsFromTheAttheMarketOfferingNet
usd
CY2023Q1 cwbr Lab Services Supplies
LabServicesSupplies
7131 usd
CY2022Q4 cwbr Lab Services Supplies
LabServicesSupplies
160482 usd
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
42382 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
167386 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
49513 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
327868 usd
CY2023Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
400000 usd
CY2023Q1 cwbr Debt Interest Amount
DebtInterestAmount
100000 usd
CY2023Q1 cwbr Royalties Ranging Percentage
RoyaltiesRangingPercentage
0.08 pure
CY2023Q1 us-gaap Retail Land Sales Receivables Stated Interest Rate
RetailLandSalesReceivablesStatedInterestRate
0.12 pure
CY2022Q3 cwbr Rent Expense For Space
RentExpenseForSpace
13080 usd
CY2022Q1 us-gaap Payments For Rent
PaymentsForRent
100000 usd
CY2023Q1 us-gaap Payments For Rent
PaymentsForRent
100000 usd
CY2023Q1 cwbr Issuance And Sale Of Stock
IssuanceAndSaleOfStock
17000000 shares
CY2023Q1 us-gaap Excess Stock Shares Authorized
ExcessStockSharesAuthorized
12000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 cwbr Amount Of Atm Availability
AmountOfATMAvailability
200000 usd
CY2023Q1 us-gaap Multiemployer Plans Collective Bargaining Arrangement Expiration Date Description
MultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription
The Company’s ATM program expires in September 2023.
CY2023Q1 cwbr Options To Purchase Common Stock
OptionsToPurchaseCommonStock
64900 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
317857 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
194853 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
44.53
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
38.53
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
38.53
CY2023Q1 cwbr Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 One
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2One
P6Y11M26D
CY2023Q1 cwbr Stock Options Outstan Share Based Compensation Arrangement By Share Based Payment Award Option Forfeitures And Expirations In Periodding Cancelledin Share
StockOptionsOutstanShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresAndExpirationsInPerioddingCancelledinShare
64863 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
252994 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
195192 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
46.03
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
40.21
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
40.21
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M17D
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
252994 shares
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
195192 shares
CY2023Q1 cwbr Stock Issued During Period Shares Stock Warrants Expired
StockIssuedDuringPeriodSharesStockWarrantsExpired
900 shares
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
337601 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
456423 usd
CY2023Q1 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
63481 usd
CY2022Q1 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
32801 usd
CY2023Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
401082 usd
CY2022Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
489224 usd
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
8350 usd
CY2022Q1 us-gaap Other Expenses
OtherExpenses
8350 usd
CY2023Q1 cwbr Total Noncash Expenses
TotalNoncashExpenses
401082 usd
CY2022Q1 cwbr Total Noncash Expenses
TotalNoncashExpenses
497574 usd
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
CohBar, Inc
CY2023Q1 cwbr Vendor Receivable
VendorReceivable
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2022Q1 us-gaap Revenues
Revenues
usd
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
usd
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.13
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2890878 shares
CY2023Q1 cwbr Share Based Compensations Arrangement By Shares Based Payment Award Options Exercisable Granted.
ShareBasedCompensationsArrangementBySharesBasedPaymentAwardOptionsExercisableGranted.
usd
CY2023Q1 cwbr Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1 cwbr Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePriceGranted
CY2023Q1 cwbr Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageGrantDateFairValue
CY2023Q1 cwbr Share Based Compensation Arrangement By Share Based Payment Award Options Contractual Life Years
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsContractualLifeYears
CY2023Q1 cwbr Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue
usd
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2023Q1 cwbr Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercised
shares
CY2023Q1 cwbr Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercised
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercised
CY2023Q1 cwbr Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Exercise
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePriceExercise
CY2023Q1 cwbr Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Exercised Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue
CY2023Q1 cwbr Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Contractual Life Years
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedContractualLifeYears
CY2023Q1 cwbr Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedIntrinsicValue
usd
CY2023Q1 cwbr Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Cancelled
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableCancelled
shares
CY2023Q1 cwbr Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Cancelled
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageCancelled
CY2023Q1 cwbr Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Cancelled
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePriceCancelled
CY2023Q1 cwbr Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Cancelled Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageCancelledDateFairValue
CY2023Q1 cwbr Share Based Compensation Arrangement By Share Based Payment Award Options Cancelledd Contractual Life Years
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelleddContractualLifeYears
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
usd
CY2023Q1 us-gaap Other Expenses
OtherExpenses
usd
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001522602

Files In Submission

Name View Source Status
0001213900-23-039321-index-headers.html Edgar Link pending
0001213900-23-039321-index.html Edgar Link pending
0001213900-23-039321.txt Edgar Link pending
0001213900-23-039321-xbrl.zip Edgar Link pending
cwbr-20230331.xsd Edgar Link pending
f10q0323ex31-1_cohbar.htm Edgar Link pending
f10q0323ex31-2_cohbar.htm Edgar Link pending
f10q0323ex32-1_cohbar.htm Edgar Link pending
f10q0323_cohbar.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cwbr-20230331_cal.xml Edgar Link unprocessable
cwbr-20230331_def.xml Edgar Link unprocessable
cwbr-20230331_pre.xml Edgar Link unprocessable
cwbr-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
f10q0323_cohbar_htm.xml Edgar Link completed